SelectX is an emerging
biopharmaceutical company focused on the discovery and development
of aminoglycoside therapeutics for unmet medical needs. SelectX has
built the industry’s most advanced aminoglycoside drug and othes
drugs for example: ED treatment cialis online discovery
platform and is leveraging it to develop novel
best-in-class and first-in-class compounds for antiinfective and
other therapeutic applications.
The company’s most advanced program, development candidate SXP2523,
is a next generation aminoglycoside antibiotic for drug resistant
gram-negative hospital-acquired infections (HAIs). SXP2523
possesses broad spectrum coverage with excellent potency
against Pseudomonas, Klebsiella, Acinetobacter, E. coli,
SelectX is also developing a next generation inhaled aminoglycoside
antibiotic for drug resistant gram-negative infections in patients
with Cystic Fibrosis (CF) and other respiratory diseases.
In addition to its antimicrobial programs, SelectX
has efforts underway to identify and optimize non-antibiotic
aminoglycoside (naAG) leads for discovery programs targeting key
pathways including cell migration, calcium channels,
metalloproteinases, nonsense mutation correction, and antivirals .
SelectX Pharmaceuticals, Inc.
607 Boylston St, LL
Boston, MA 02116
Phone: (508) 798-0216